Bayer | GenomeWeb

Bayer

Companion diagnostics developed under the deal will be based on RNAscope and immunohistochemistry technology.

The deal gives Bayer access to the T2 Magnetic Resonance technology for drug discovery and biomarker research in certain hemostasis programs.

The deal with ERS Genomics, a commercialization vehicle for Emmanuelle Charpentier's patents, gives the Bayer LifeScience Center access to CRISPR/Cas9 genome editing.

The company's Avatar platform cultures and propagates a variety of cell types in an in vivo-like environment to yield more accurate and relevant molecular analyses.

The JV will be based in London with operations in Cambridge, Massachusetts and will develop new treatments for blood disorders, blindness, and congenital heart disease.

The deal expands one reached in 2013 to discover and develop therapeutic agents targeting cancer genome alterations. 

NEW YORK (GenomeWeb) – Finland-based bioinformatics firm MediSapiens said this week that it is ramping up its US operations, including moving its East Cost subsidiary to a bigger office space in Cambridge, Mass., preparing to launch a new website, and planning to hire new staff, most likely in bu

NEW YORK (GenomeWeb) – MediSapiens has announced that it will provide its software solution, dubbed the Integrated Genomics Platform, to Bayer Healthcare.

NEW YORK (GenomeWeb) – Cenix Biosciences this week announced that it has signed an agreement to provide RNAi-based high-content screening services to Germany's Bayer Pharma.

NEW YORK (GenomeWeb News) – A consortium of European research institutions and private partners will use €5.3 million ($7.4 million) in funding to develop a microfluidics-based lab-on-a-chip device to identify and measure the concentration of circulating tumor cells in blood, one of the partners,

Pages

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.